{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:28:32Z","timestamp":1768408112066,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T00:00:00Z","timestamp":1467936000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s10157-016-1304-6","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T10:21:18Z","timestamp":1467973278000},"page":"417-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial"],"prefix":"10.1007","volume":"21","author":[{"given":"Genjiro","family":"Kimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1833-9075","authenticated-orcid":false,"given":"Masato","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ueshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Yasuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Imamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuwa","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,8]]},"reference":[{"issue":"11","key":"1304_CR1","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1097\/01.ASN.0000133698.80390.37","volume":"15","author":"FA El-Atat","year":"2004","unstructured":"El-Atat FA, Stas SN, McFarlane SI, Sowers JR. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol. 2004;15(11):2816\u201327.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1304_CR2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","volume":"2","author":"J Shepherd","year":"2007","unstructured":"Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the treating to new targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"1304_CR3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/ndt\/gfl538","volume":"22","author":"VG Athyros","year":"2007","unstructured":"Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, Tziomalos K, Ganotakis ES, Elisaf M. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transpl. 2007;22(1):118\u201327.","journal-title":"Nephrol Dial Transpl"},{"issue":"7","key":"1304_CR4","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1681\/ASN.2006010012","volume":"17","author":"S Sandhu","year":"2006","unstructured":"Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006\u201316.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1304_CR5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2010.07.053","volume":"213","author":"RG Fassett","year":"2010","unstructured":"Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. Effect of atorvastatin on kidney function in chronic kidney disease: a randomized double-blind placebo-controlled trial. Atherosclerosis. 2010;213(1):218\u201324.","journal-title":"Atherosclerosis."},{"issue":"2","key":"1304_CR6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10157-012-0676-5","volume":"17","author":"K Ueshima","year":"2013","unstructured":"Ueshima K, Kasahara M, Koya D, Babazono T, Sato T, Imamoto M, Yasuno S, Fujimoto A, Tanaka S, Kimura G, Nakao K. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial. Clin Exp Nephrol. 2013;17(2):211\u20137.","journal-title":"Clin Exp Nephrol."},{"issue":"2","key":"1304_CR7","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.atherosclerosis.2009.03.031","volume":"206","author":"H Nakamura","year":"2009","unstructured":"Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y, MEGA Study Group. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009;206(2):512\u20137.","journal-title":"Atherosclerosis."},{"issue":"10","key":"1304_CR8","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1161\/01.STR.31.10.2442","volume":"31","author":"U Laufs","year":"2000","unstructured":"Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31(10):2442\u20139.","journal-title":"Stroke"},{"issue":"2","key":"1304_CR9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ajh.2008.325","volume":"22","author":"JN Cohn","year":"2009","unstructured":"Cohn JN, Wilson DJ, Neutel J, Houston M, Weinberger MH, Grimm R Jr, Smith DH, Sun W. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens. 2009;22(2):137\u201344.","journal-title":"Am J Hypertens"},{"key":"1304_CR10","doi-asserted-by":"crossref","unstructured":"Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006; 17; 47(2):332\u20137.","DOI":"10.1016\/j.jacc.2005.06.088"},{"issue":"3","key":"1304_CR11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.5414\/CN107621","volume":"79","author":"Z Katzir","year":"2013","unstructured":"Katzir Z, Leibovitch E, Vaknin H, Schreiber L, Berger E, Matas Z, Fux A, Boaz M, Briliant A, Biro A. Effect of atorvastatin on IgA nephropathy in the rat. Clin Nephrol. 2013;79(3):214\u201320.","journal-title":"Clin Nephrol"},{"key":"1304_CR12","doi-asserted-by":"crossref","unstructured":"Shibata T, Tamura M, Kabashima N, Serino R, Tokunaga M, Matsumoto M, Miyamoto T, Miyazaki M, Furuno Y, Takeuchi M, Abe H, Okazaki M, Otsuji Y. Fluvastatin attenuates IGF-1-induced ERK1\/2 activation and cell proliferation by mevalonic acid depletion in human mesangial cells. Life Sci. 2009; 22; 84(21\u201322):725\u201331.","DOI":"10.1016\/j.lfs.2009.02.022"},{"issue":"2","key":"1304_CR13","first-page":"84","volume":"2","author":"M Shimojima","year":"2012","unstructured":"Shimojima M, Kawashiri MA, Nitta Y, Yoshida T, Katsuda S, Kaku B, Taguchi T, Hasegawa A, Konno T, Hayashi K, Yamagishi M. Rapid changes in plaque composition and morphology after intensive lipid lowering therapy: study with serial coronary CT angiography. Am J Cardiovasc Dis. 2012;2(2):84\u20138.","journal-title":"Am J Cardiovasc Dis."},{"issue":"7","key":"1304_CR14","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0735-1097(98)00487-2","volume":"32","author":"C Bustos","year":"1998","unstructured":"Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, D\u00edaz C, Hern\u00e1ndez G, Egido J. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32(7):2057\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1304_CR15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","volume":"3","author":"D Zeeuw De","year":"2015","unstructured":"De Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, Monyak JT, Parving HH, Remuzzi G, Sowers JR, Vidt DG. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015;3(3):181\u201390.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"1304_CR16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","volume":"54","author":"HM Colhoun","year":"2009","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH, CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the collaborative atorvastatin diabetes study (CARDS). Am J Kidney Dis. 2009;54(5):810\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"1304_CR17","doi-asserted-by":"crossref","first-page":"608","DOI":"10.5551\/jat.11312","volume":"19","author":"Y Tamura","year":"2012","unstructured":"Tamura Y, Murayama T, Minami M, Matsubara T, Yokode M, Arai H. Ezetimibe ameliorates early diabetic nephropathy in db\/db mice. J Atheroscler Thromb. 2012;19(7):608\u201318.","journal-title":"J Atheroscler Thromb."},{"issue":"3","key":"1304_CR18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.metabol.2011.07.004","volume":"61","author":"Y Mori","year":"2012","unstructured":"Mori Y, Hirano T. Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5\/6 nephrectomized rats fed high-cholesterol. Metabolism. 2012;61(3):379\u201388.","journal-title":"Metabolism."},{"issue":"4","key":"1304_CR19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2169\/internalmedicine.53.0649","volume":"53","author":"T Morita","year":"2014","unstructured":"Morita T, Morimoto S, Nakano C, Kubo R, Okuno Y, Seo M, Someya K, Nakahigashi M, Ueda H, Toyoda N, Kusabe M, Jo F, Takahashi N, Iwasaka T, Shiojima I. Renal and vascular protective effects of ezetimibe in chronic kidney disease. Intern Med. 2014;53(4):307\u201314.","journal-title":"Intern Med"},{"issue":"2","key":"1304_CR20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0003319713519492","volume":"66","author":"GN Kouvelos","year":"2015","unstructured":"Kouvelos GN, Arnaoutoglou EM, Milionis HJ, Raikou VD, Papa N, Matsagkas MI. The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology. 2015;66(2):128\u201335.","journal-title":"Angiology."}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-016-1304-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1304-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1304-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1304-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T18:35:21Z","timestamp":1568140521000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-016-1304-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,8]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["1304"],"URL":"https:\/\/doi.org\/10.1007\/s10157-016-1304-6","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,8]]}}}